CMS Extends Skilled Nursing Facility Medicare Revalidation Deadline to August 2025
CMS extends skilled nursing facilities' Medicare revalidation deadline to August 2025 amid new ownership disclosure requirements to improve care quality oversight.
CMS extends skilled nursing facilities' Medicare revalidation deadline to August 2025 amid new ownership disclosure requirements to improve care quality oversight.
Analysis of Medicare affordability challenges highlights systemic issues and the need for reform in traditional Medicare and Medicare Advantage plans affecting coverage and costs.
Explore the TRICARE For Life Handbook to understand automatic eligibility, comprehensive Medicare coordination, and pharmacy coverage options for TRICARE beneficiaries transitioning to Medicare.
CMS finalizes critical 2026 Medicare Advantage rule changes, including anti-obesity drug coverage exclusion, AI regulatory deferral, and limits on retroactive inpatient stay denials affecting payers and providers.
Elevance Health reports steady Q1 profits with growth in Medicare Advantage and Carelon despite elevated medical costs and legal challenges.
Elevance Health's Q1 report shows Medicare Advantage utilization in line with expectations, Medicaid rate progress, and ACA expansion amid market volatility.
Explore how Medicare covers diabetes treatments and costs including Metformin and other diabetic supplies under Parts A, B, C, and D. Understand cost factors like premiums and deductibles.
The Trump administration has ceased federal Medicaid funding for non-healthcare services, refocusing resources on core medical benefits amid rising spending on social determinants of health programs in several states.
Mark Farrah Associates reports a slowdown in Medicare Advantage market growth with detailed enrollment and market share data for early 2025. Key tools aid insurers in competitive analysis post-Open Enrollment Period.
April 2025 market update reveals insurer stock declines amid UnitedHealth earnings miss, offset by pharma gains led by Eli Lilly's drug innovation and strong healthcare sector earnings projections.